BioPharmSignal logoBioPharmSignal

Biotech News

Erasca Announces Multiple Presentations at the Upcoming 38th EORTC-NCI-AACR Symposium

Erasca (ERAS)ErascaClinical readout

Oral presentation to share updated monotherapy clinical data for ERAS-0015 including additional patients and longer follow-up, expanding on the previously reported preliminary results from the ongoing AURORAS-1 Phase 1 trial Poster presentation to share nonclinical combination data of ERAS-0015 and

Related news

ERASErasca2026-07-13 20:01 EST

Erasca Announces Updated Preliminary Phase 1 Data and Registration-Enabling Plans for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015 in KRAS-Mutant Solid Tumors

ERASErasca2026-08-24 12:00 EST

Erasca Granted FDA Fast Track Designation for Pan-RAS Molecular Glue ERAS-0015 in Patients with Metastatic Pancreatic Adenocarcinoma

KYMRKymera2026-09-01 11:00 EST

Kymera Therapeutics Announces Presentations on KT-621, a First-in-Class, Oral STAT6 Degrader, at the European Respiratory Society and European Academy of Dermatology & Venereology Congresses

BMYBMYBristol-Myers Squibb Company2026-09-08 10:59 EST

Bristol Myers Squibb Announces Positive Topline Results from Registrational Phase 2 QUINTESSENTIAL Trial of the Potential First-in-Class GPRC5D-Directed CAR T Cell Therapy, Arlocabtagene Autoleucel ...

FATEFate Therapeutics2026-08-14 11:00 EST

Fate Therapeutics Initiates Potentially Registrational RECLAIM-LN Clinical Trial of FT819 for the Treatment of Lupus Nephritis

LYELLyell Immunopharma2026-09-10 20:05 EST

Lyell Immunopharma Completes Manufacturing Transfer for LYL273 and Provides Updated Timeline on Phase 1/2 Trial in Metastatic Colorectal Cancer

IDYAIDEAYA Biosciences2026-09-09 10:00 EST

IDEAYA Biosciences and Servier Announce First Patient Dosed in OptimUM-11 Global Phase 3 Registrational Trial of Darovasertib and Crizotinib as Adjuvant Therapy for Subjects with Uveal Melanoma

RVMDRevolution Medicines2026-09-02 21:50 EST

New England Journal of Medicine Publishes Phase 1/2 Clinical Data on Revolution Medicines’ RASONQUE™ (daraxonrasib) in Metastatic Non-Small Cell Lung Cancer

NRIXNurix Therapeutics2026-08-04 11:00 EST

Nurix Announces $10 Million Milestone Payment Associated with Initiation of a Phase 1 Clinical Trial of a STAT6 Degrader

NRIXNurix Therapeutics2026-08-04 05:00 EST

Nurix Therapeutics Announces First Patient Enrolled in Registrational Phase 3 DAYBreak CLL-306 Trial of Bexobrutideg in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

View all latest news

Erasca

RAS/MAPK Precision Oncology Erasca is a clinical-stage precision-oncology company developing therapies for cancers driven by the RAS/MAPK pathway. Its portfolio is designed to address genetically defined tumors through direct RAS inhibition. ERAS-0015 ERAS-0015 is a pan-RAS molecular glue being evaluated in the AURORAS clinical program....

Recent company news

ERASErasca2026-09-10 12:00 EST

Erasca Announces Multiple Presentations at the Upcoming 38th EORTC-NCI-AACR Symposium

ERASErasca2026-09-08 11:00 EST

Erasca to Present at the Morgan Stanley 24th Annual Global Healthcare Conference

ERASErasca2026-08-24 12:00 EST

Erasca Granted FDA Fast Track Designation for Pan-RAS Molecular Glue ERAS-0015 in Patients with Metastatic Pancreatic Adenocarcinoma

ERASErasca2026-08-11 20:01 EST

Erasca Reports Second Quarter 2026 Business Updates and Financial Results

ERASErasca2026-08-10 20:01 EST

Erasca Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Stock data

Close
15.34 USD
Market cap
4.19B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States